Dimensional Fund Advisors LP Buys Shares of 104,437 Climb Bio, Inc. $CLYM

Key Points

• Dimensional Fund Advisors acquired 104,437 shares of Climb Bio, valued at approximately $715,000, giving it a 0.22% stake. Institutional investors and hedge funds collectively own 69.76% of the company.
• Wall Street maintains a favorable outlook, with an average rating of “Buy” and a consensus price target of $22.75; recent targets range from $18 to $25.
• Climb Bio shares opened at $16.33 and have risen 10.9%, near their 12-month high of $17.00. The company reported a quarterly loss of $0.18 per share, beating expectations for a $0.21 loss.

Dimensional Fund Advisors LP purchased a new position in Climb Bio, Inc. (NASDAQ:CLYM - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 104,437 shares of the company's stock, valued at approximately $715,000. Dimensional Fund Advisors LP owned about 0.22% of Climb Bio at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC acquired a new stake in Climb Bio during the 1st quarter worth $27,000. Qube Research & Technologies Ltd purchased a new position in shares of Climb Bio in the second quarter worth about $43,000. Virtu Financial LLC acquired a new position in Climb Bio during the fourth quarter worth about $43,000. Blair William & Co. IL acquired a new position in Climb Bio during the fourth quarter worth about $44,000. Finally, Marshall Wace LLP purchased a new stake in Climb Bio during the 2nd quarter valued at about $46,000. 69.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on CLYM. Robert W. Baird set a $21.00 price objective on shares of Climb Bio in a report on Wednesday, May 6th. Truist Financial upped their price target on Climb Bio from $17.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Oppenheimer increased their price target on Climb Bio from $10.00 to $18.00 and gave the company an "outperform" rating in a report on Tuesday, April 21st. BTIG Research lifted their price objective on Climb Bio from $19.00 to $20.00 and gave the stock a "buy" rating in a research report on Thursday, June 11th. Finally, Wall Street Zen raised Climb Bio from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $22.75.

Climb Bio Trading Up 10.9%

Climb Bio stock opened at $16.33 on Friday. The company has a 50-day moving average price of $12.72 and a 200 day moving average price of $9.65. Climb Bio, Inc. has a 12-month low of $1.54 and a 12-month high of $17.00. The stock has a market cap of $938.00 million, a P/E ratio of -19.67 and a beta of 0.08.

Climb Bio (NASDAQ:CLYM - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03. As a group, analysts forecast that Climb Bio, Inc. will post -0.84 EPS for the current year.

Climb Bio Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.

Want to see what other hedge funds are holding CLYM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Climb Bio, Inc. (NASDAQ:CLYM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source